Roy Buchanan
Stock Analyst at Citizens Capital Markets
(0.88)
# 3,636
Out of 4,784 analysts
56
Total ratings
28.85%
Success rate
-21.58%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Reiterates: Market Outperform | $5 | $1.39 | +259.71% | 8 | Mar 26, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.73 | +940.46% | 3 | Mar 14, 2025 | |
| CDTX Cidara Therapeutics | Initiates: Market Outperform | $46 | $22.39 | +105.45% | 1 | Mar 12, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $2.98 | +436.91% | 8 | Feb 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $47.71 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.50 | +166.67% | 3 | Feb 11, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $21 | $5.71 | +267.78% | 12 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $1.41 | +892.91% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.43 | +413.22% | 1 | Jan 10, 2025 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | $24 → $7 | $1.18 | +493.22% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.50 | +42.86% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $27 | $13.68 | +97.37% | 5 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $589.15 | -23.96% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $6.74 | +137.39% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.12 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $2.74 | +15,228.47% | 1 | Sep 14, 2021 | |
AN2 Therapeutics
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $1.39
Upside: +259.71%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.73
Upside: +940.46%
Cidara Therapeutics
Mar 12, 2025
Initiates: Market Outperform
Price Target: $46
Current: $22.39
Upside: +105.45%
CureVac
Feb 14, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $2.98
Upside: +436.91%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $47.71
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.50
Upside: +166.67%
Enanta Pharmaceuticals
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $5.71
Upside: +267.78%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $1.41
Upside: +892.91%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.43
Upside: +413.22%
HOOKIPA Pharma
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.18
Upside: +493.22%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.50
Upside: +42.86%
Nov 3, 2023
Maintains: Market Outperform
Price Target: $25 → $27
Current: $13.68
Upside: +97.37%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $589.15
Upside: -23.96%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $6.74
Upside: +137.39%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.12
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $2.74
Upside: +15,228.47%